论文部分内容阅读
目的评价恩度(重组人血管内皮抑素,endostar,YH-16)联合GP(吉西他滨+顺铂)治疗老年性晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法 72例老年性晚期NSCLC患者被随机分为两组,试验组(40例)应用YH-16联合GP方案,对照组(32例)予以常规GP方案化疗。两组患者均至少完成2个周期。结果试验组有效率(RR)为42.5%,临床获益率(CBR)为80.0%;对照组有效率(RR)28.13%,临床获益率(CBR)为56.2%。两组毒副反应相似,患者的主要毒副反应有恶心、呕吐、白细胞减少等。结论恩度联合GP方案治疗老年性晚期NSCLC是一种有效、安全的方案。
Objective To evaluate the efficacy and safety of Endo (recombinant human endostar, YH-16) and GP (gemcitabine plus cisplatin) in the treatment of senile advanced non-small cell lung cancer (NSCLC). Methods Seventy-two elderly patients with advanced NSCLC were randomly divided into two groups. The experimental group (40 cases) received YH-16 combined with GP regimen, while the control group (32 cases) received conventional GP regimen. Both groups completed at least 2 cycles. Results The effective rate (RR) of trial group was 42.5% and the clinical benefit rate (CBR) was 80.0%. The control group was 28.13% and the clinical benefit rate was 56.2%. Side effects similar to the two groups, the patient’s main side effects are nausea, vomiting, leukopenia and so on. Conclusion Endood combined with GP regimen in the treatment of senile advanced NSCLC is an effective and safe protocol.